title: Celiac disease 2015 update: new therapies.
abstract: Celiac disease (CD) is a chronic, small intestinal, immune-mediated enteropathy triggered by exposure to dietary gluten in genetically susceptible individuals. Currently, lifelong adherence to a gluten-free diet (GFD) is the only available treatment. However, GFD alone is not sufficient to relieve symptoms, control small intestinal inflammation and prevent long-term complications in many patients. The GFD has its challenges including issues related to adherence, lifestyle restrictions and cost. As a result, there is growing interest in and a need for non-dietary therapies to manage this condition. In recent years, different targets in the immune-mediated cascade of CD have been identified in clinical and pre-clinical trials for potential therapies. This review will discuss the latest non-dietary therapies in CD, including endopeptidases, modulators of enterocyte tight junctions and agents involved in gluten tolerization and immunomodulation. We will also discuss the potential implications of approved therapeutics on CD clinical practice.
authors: Department of Medicine, Celiac Center, Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
authors: Gopal
authors: G
authors: Veeraraghavan
authors: Daniel A
authors: DA
authors: Leffler
authors: Dharmesh H
authors: DH
authors: Kaswala
authors: Rupa
authors: R
authors: Mukherjee
mesh_terms: D002446:Celiac Disease / Q000276:immunology* / Q000628:therapy*; D003131:Combined Modality Therapy; D055050:Diet, Gluten-Free; D055808:Drug Discovery; D010450:Endopeptidases / Q000627:therapeutic use*; D020895:Enterocytes / Q000187:drug effects; D019204:GTP-Binding Proteins / Q000037:antagonists & inhibitors; D005983:Glutens / Q000276:immunology* / Q000378:metabolism; D006725:Hookworm Infections / Q000276:immunology; D006801:Humans; D056747:Immunomodulation; D058990:Molecular Targeted Therapy; D009842:Oligopeptides / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D019108:Tight Junctions / Q000187:drug effects; D011503:Transglutaminases / Q000037:antagonists & inhibitors; D014612:Vaccines / Q000627:therapeutic use
chemical_list: D009842:Oligopeptides; D014612:Vaccines; D005983:Glutens; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases; D010450:Endopeptidases; D019204:GTP-Binding Proteins; C525167:larazotide acetate
keywords: ALV003; AT-1001; CCR9 antagonist; Necator americanus; Nexvax2; celiac disease; drug therapy; gluten-free diet; larazotide acetate; tTG inhibitors